Shares of Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) have earned a consensus rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last […]
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) SVP Mikhail Eydelman sold 1,667 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $73.87, for a total transaction of $123,141.29. Following the completion of the transaction, the senior vice president now owns 20,710 shares of […]
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) SVP Mikhail Eydelman sold 1,667 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $73.87, for a total transaction of $123,141.29. Following the transaction, the senior vice president now owns 20,710 shares in the company, valued […]
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) Director Heath Lukatch sold 5,000 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $71.50, for a total transaction of $357,500.00. Following the completion of the sale, the director now directly owns 5,625 shares in the […]
SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity.